ArticleBMC bioinformatics2022
In-silico design of an immunoinformatics based multi-epitope vaccine against Leishmania donovani.
Article in BMC bioinformatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 43 citations in OpenAlex.
- Pangenome-GuidedPharmaceuticals (Basel, Switzerland) · 2026Article
- Screening strategy for the selection of Leishmania spp. epitopes in humans through molecular interactions analysis: A bioinformatics approachBiomedica : revista del Instituto Nacional de Salud · 2026Article
- Immunogenicity of a Recombinant Multi-Epitope Vaccine Incorporating GRA14, SAG1, and GRA1 Antigens ofVaccines · 2026Article
- Epitope prediction and immunogenicity assessment of Leishmania donovani TryS protein as a potential vaccine candidate.Immunologic research · 2026Article
- In silico design of a multi-epitope vaccine targeting DENV-1 and DENV-3.Scientific reports · 2026Article
- Leishmaniasis.Nature reviews. Disease primers · 2025Review
- Design of a novel multi epitope antigen for diagnosis of visceral leishmaniasis using an immunoinformatics approach.Scientific reports · 2025Article
- Integrative genomic and immunoinformatic approach for characterizing HIV-1 pol, vpr, and Nef genes and designing a multi-epitope vaccine.Scientific reports · 2025Article
- Towards precision epitopes based vaccine againstBiochemistry and biophysics reports · 2025Article
- Design of a Multi-Epitope Vaccine Based onInternational journal of molecular sciences · 2025Article
- Immunoinformatics based designing of a multi-epitope cancer vaccine targeting programmed cell death ligand 1.Scientific reports · 2025Article
- Molecular and Immunological Properties of a Chimeric Glycosyl Hydrolase 18 Based on Immunoinformatics Approaches: A Design of a New Anti-ACS pharmacology & translational science · 2025Article
- Using immunoinformatics and bioinformatics approach to design novel and effective rational in-silico vaccine against humanIn silico pharmacology · 2025Article
- In silico design and assessment of a multiepitope and multiantigen potential vaccine candidate againstIn silico pharmacology · 2025Article
- Rational design of multi-epitope vaccine for Chandipura virus using an immunoinformatics approach.PloS one · 2025Article
- Development of multi-epitope Cathepsin L driven short peptide vaccine againstFrontiers in veterinary science · 2025Article
- Article
- In silico identification and ex vivo evaluation of Toxoplasma gondii peptides restricted to HLA-A*02, HLA-A*24 and HLA-B*35 alleles in human PBMC from a Colombian population.Medical microbiology and immunology · 2024Article
- Exploring Bioinformatics Solutions for Improved Leishmaniasis Diagnostic Tools: A Review.Molecules (Basel, Switzerland) · 2024Review
- Multi-epitopes vaccine design for surface glycoprotein against SARS-CoV-2 using immunoinformatic approach.Heliyon · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVisceral Leishmaniasis (VL) is a fatal vector-borne parasitic disorder occurring mainly in tropical and subtropical regions. VL falls under the category of neglected tropical diseases with growing drug resistance and lacking a licensed vaccine. Conventional vaccine synthesis techniques are often very laborious and challenging. With the advancement of bioinformatics and its application in immunology, it is now more convenient to design multi-epitope vaccines comprising predicted immuno-dominant epitopes of multiple antigenic proteins. We have chosen four antigenic proteins of Leishmania donovani and identified their T-cell and B-cell epitopes, utilizing those for in-silico chimeric vaccine designing. The various physicochemical characteristics of the vaccine have been explored and the tertiary structure of the chimeric construct is predicted to perform docking studies and molecular dynamics simulations.
resultsThe vaccine construct is generated by joining the epitopes with specific linkers. The predicted tertiary structure of the vaccine has been found to be valid and docking studies reveal the construct shows a high affinity towards the TLR-4 receptor. Population coverage analysis shows the vaccine can be effective on the majority of the world population. In-silico immune simulation studies confirms the vaccine to raise a pro-inflammatory response with the proliferation of activated T and B cells. In-silico codon optimization and cloning of the vaccine nucleic acid sequence have also been achieved in the pET28a vector.
conclusionThe above bioinformatics data support that the construct may act as a potential vaccine. Further wet lab synthesis of the vaccine and in vivo works has to be undertaken in animal model to confirm vaccine potency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.